Q4 2024 GeoVax Labs Inc Earnings Call
So go for a ride
<unk> product candidate receive regulatory oversight.
To be licensed.
G box rates as required capital to complete development of its products.
Development of competitive products that may be more effective.
Shield products.
<unk> will be able to enter into a favorable manufacturing and distribution agreements and other factors.
Okay.
<unk> assumes no obligation to update these forward looking statements.
To do so.
More information about these factors is contained.
With the Securities and Exchange Commission, including those set forth at risk factors. This Form 10-K.
It is now my pleasure to introduce the chairman and CEO.
David Dodd: David Dodd.
David Dodd: Welcome to fourth quarter full year, 2024, <unk> corporate update call.
David Dodd: Following my comments Mark Reynolds, our CFO will provide an update of our financials and then we will address any questions you may have.
David Dodd: 'twenty 'twenty four and included several major events of the development of <unk> led by the BARDA Project Nextgen Award valued at almost $400 million being announced during mid June in support of Geo's CMO Paz, one our next generation COVID-19 vaccine.
David Dodd: This program is underway with confirmation of all study sites manufacturing in support of vaccine product is underway and we continue our ongoing billings for Bart.
David Dodd: Relative to G O N V. A vaccine candidate against imports in smallpox. During Q4, we completed cgmp product and quality release of the clinical path of G. O N V. A.
David Dodd: We anticipate having available vaccine or clinical evaluation in the second half of this year.
David Dodd: We're pleased to state that we produce sufficient amount of product support the anticipated clinical valuation as well as additional product in support of potential additional clinical use in conjunction with various stakeholder discussions that we have under what.
David Dodd: Relative to our plans for phase two good depth in trial. The clinical operations plans are underway as we complete the necessary regulatory aspects and product manufacturing in support of the trial.
David Dodd: In addition, we are moving forward with our advanced N V. A manufacturing process utilizing our <unk> one master cell bank.
David Dodd: This process is implemented.
David Dodd: We anticipate the ability to produce significantly more MVA based vaccine material much faster utilizing a flexible process to support local decentralized vaccine manufacturing, while reducing the manufacturing cost significantly.
David Dodd: Our goal is to successfully develop innovative cancer therapies and infectious disease vaccine.
David Dodd: And critically important unmet medical need pursuing initial indications that support expedited registration pathways.
David Dodd: We anticipate establishing business partnership and collaboration and support of worldwide development commercialization and distribution.
David Dodd: Our priorities anticipated milestones for 2025 remain focused on.
David Dodd: Advancing CEO CMO cost, one, especially relative to project next week.
David Dodd: We remain in close contact with BARDA in support of plasma initiate the trial later this year or in early 2020.
David Dodd: The clear need to fill the gap reflected in the FERC generation COVID-19 vaccine and we believe that Geo CMO fourth one has the potential as well as expanded value to fill this gap relative to the 40 plus million immuno compromised adults in the U S. Currently not served well by the authorized back pain.
David Dodd: Our vaccine uses a proven safe and efficient delivery platform modified vaccinia anchor or NBA, which does not replicate in mammalian cells. The safety of MBA has been well established and accepted by regulatory authorities worldwide, especially among patients with weakened immune systems as well.
David Dodd: Among pregnant women.
David Dodd: MBA is well characterized well known and accepted by regulatory authorities worldwide.
David Dodd: Simply no outstanding questions pertaining to protect the safety issues and uses within various critically important patient population, which may not be the case for alternative vaccine technology.
David Dodd: Our vaccine platform MVA is also a standalone vaccine authorized for protection against imports in smallpox.
David Dodd: This is a unique feature with critically important clinical benefits, providing a significant differentiator will see M. O ask one, especially when considered as a potential COVID-19 vaccine in regions, where it impacts it in general.
David Dodd: Finally in addition to its benefits are immunocompromised individuals, we believe that see them or if one has the potential for broader use header.
David Dodd: Heterolysin booster Clark mrna vaccine, providing a durable abroad.
David Dodd: In response against emerging variants.
David Dodd: Infrequent possibility.
David Dodd: <unk> one third by virtue of this immune profile reduce the need for continuous vaccine with the.
David Dodd: Reconfiguration that appears necessary.
David Dodd: M R RNA vaccines.
David Dodd: In fact, the HHS press release announcing the project next Gen Award in support of CMO fourth one specifically highlighted that our vaccine holds the potential for a COVID-19 vaccine that provide broader protection, meaning encompassing a wider array of merit and the potential for increased durability.
David Dodd: In other words longer lasting than that evidenced by the current authorized vaccine.
David Dodd: Most important we believe is the value to immuno compromised patient populations, who are currently not served well by the first generation COVID-19 vaccine.
David Dodd: Thus far the clinical data from our phase II studies is supportive of these potential next generation benefits.
David Dodd: Beyond the Nextgen trial, three phase III clinical trials are underway with CMO for <unk>, what's the gross populations of immuno compromised patients at high risk for developing severe COVID-19.
David Dodd: The phase II trial evaluates our vaccine as a hurdle.
David Dodd: Booster among healthy adult followed the prior receipt of an mrna vaccine I won't delve further into the specific trials at this time, but we welcome any questions you may have during our Q&A session.
David Dodd: Overall, we hope to demonstrate that our COVID-19 vaccine successfully addresses the current unmet needs among the tens of millions if not hundreds of millions on a global basis of immuno compromised patients. While also demonstrating the vaccine as a more robust durable booster vaccine used in conjunction with first generation vaccine.
David Dodd: During 2025, we anticipate multiple presentations of clinical result for CMO cost one at various conferences.
Clothing, the upcoming World vaccine Congress of European Hematology Association, the International workshop on chronic lymphocytic leukemia, and the American Association of Immunologists further underscoring the important potential medical value of this unique next generation COVID-19 vaccine.
These presentations can also serve as important catalysts with strategic partner discussions.
With the announcement of our project Mexicana Award and the progress in our Phase III clinical studies are activities related to partnering and collaboration with CMO for US one have understandably increase we believe that CMO fourth one represents significant promise as a critically needed an important part of the COVID-19.
David Dodd: Vaccine armamentarium for public health worldwide.
David Dodd: Turning now to G O M B a R impart smallpox vaccine candidate.
David Dodd: In August 2024, the designated total declared impart as a public health emergency of international concern highlighting the critical global health threat.
David Dodd: Those by this highly virulent virus.
David Dodd: As a result of the continued spread and contagious nature of the current impasse Vera.
David Dodd: Joe has reiterated the global health Emergency Declaration in November of 2024, and even more recently on February the 27th of this year.
David Dodd: Such a declaration of a global public health threat reply within six months underscores and emphasizes the significant global health threat posed by import.
<unk> is well positioned actively progressing kill MBA and tended to disrupt the current global monopoly in this important critical area of moral.
David Dodd: Moreover, we believe that our efforts will establish <unk> as the first U S based supplier of such a vaccine potentially resulting in our initial step to revenue generation.
David Dodd: Increasingly there appears to be significant government interest in U S based supply chain versus the current overdependence on non U S suppliers.
David Dodd: The strong sentiment in favor of such Onshoring initiative remains a major national legislative focus and enters.
Speaker Change: We remain in active discussions and briefings with various stakeholders such as the White House congressional offices, BARDA, Doug Hey, Joe The Africa, CDC and others regarding our progress towards having cgmp clinical batch vaccine produced and available for clinical evaluation of potential use.
Speaker Change: <unk> is clearly underscore the critical need for expanded embarks vaccine supply as a priority for Doug H O and other public health agencies worldwide.
Speaker Change: Finally, we anticipate providing continued updates related to our advanced MBA manufacturing process targeted to enable <unk> to efficiently produce and distribute.
Speaker Change: <unk> based vaccine in response to a real time market needs.
Speaker Change: Our strategic focus on oncology, specifically related to good depth remains a major priority for 2025 as well as the future of give back.
Speaker Change: We have high expectations for the potential broad utilization of the depth and against various solid tumors, especially in combination with immune checkpoint inhibitors.
Speaker Change: Last summer, we announced our plans to evaluate the depth in combination with an immune checkpoint inhibitor among patients with locally recurrent head and neck squamous cell Carcinomas following primary therapy, and for whom resection with curative intent as plan.
Speaker Change: Our clinical operations plans for this trial are being finalized along with the regulatory aspects of necessary product manufacturing in support of the phase II study.
Speaker Change: We also look forward to the upcoming the depth and presentation at the American Association of Cross research.
Speaker Change: Dr.
Speaker Change: In addition, we're planning various animal validation studies further building a compelling basis of a potential value of the depth and addressing various solid tumors.
Speaker Change: We're confident we're on a course that will build significant shareholder and stakeholder value, while delivering critically important differentiated products that improve lives worldwide now.
Mark levels: Now I'd like to turn the presentation over to Mark levels.
Mark: <unk> Chief Financial Officer for a review of our recent.
Mark: Salt and financial status Mark.
Speaker Change: Thank you David.
Speaker Change: The details of our full year 2024 financial results are summarized in today's press release I'll start My review with the income statement.
Speaker Change: Revenues associated with our BARDA contract were approximately $4 million in 2024 versus zero in 'twenty three as the contract just began in July of June of this past year.
Speaker Change: This is a cost reimbursable contract so our revenues directly correlate with billable personnel time and incremental expenses incurred.
Speaker Change: The total contract value to Geovax is $26 million, but may increase to as much as $45 million.
Speaker Change: Note that a separate contract of $433 million was awarded two elusive to conduct our trial those revenues won't be reported in our financial statements, but the funding will go directly to supporting our clinical trial.
Speaker Change: Research and development expenses were $23 7 million in 2024 versus $27 million and 23, representing an increase of roughly $3 million or 14%.
Speaker Change: The year over year increase was primarily associated with cost manufacturing clinical trial materials and other costs associated with BARDA contract spending towards <unk> and GE MBA programs also contributed to the increase.
Speaker Change: General and administrative expenses were $5 4 million in 2024 versus $6 million in 2023, representing a decrease of 600000 or 11% associated with lower stock based compensation expense patent costs franchise tax expense and a mix of other costs.
Speaker Change: Interest income was 173000 in 2024 as compared to 776000 in 2023, primarily reflecting lower interest interest income due to lower cash balances.
Speaker Change: We also reported 21000 of interest expense in 2024 associated with the short term bridge loan that was issued and retired during the year.
Speaker Change: So overall net loss for 2024 was approximately $25 million or $4 82 per share versus $26 million in 2023 or $14 29 per share.
Speaker Change: Again, with the increase primarily being driven by manufacturing activities and costs associated with the BARDA contract.
Speaker Change: Turning now to the balance sheet.
Speaker Change: Cash balances at December 31, 2024, or $5 5 million as compared to $6 5 million and the.
Speaker Change: Prior year reflective of $24 7 million used in operating activities offset by $23 8 million in financing transactions. Our outstanding common shares currently stand at $13 9 million following our recent financing activity.
Speaker Change: Supporting the BARDA contract next Gen Award.
Speaker Change: <unk> to be our top priority in terms of operational focus and a significant use of our internal R&D staff.
Speaker Change: It's important to keep in mind that this entire clinical program is fully funded by BARDA through the awards to <unk> and tour Lucent, our CRO partner.
Speaker Change: In terms of our funding needs are current and planned clinical programs for <unk> one and.
Speaker Change: <unk> and G E M. P will be the most significant use of our cash for the foreseeable future.
Speaker Change: We continue to explore various strategies to fund these development programs for several valuation inflexion points and extend our cash runway.
Speaker Change: These could include strategic partnerships additional non dilutive funding and additional offerings of our common stock.
David Dodd: Now I'll be happy to answer any questions during the Q&A period, and I will now turn the call back to David.
David Dodd: Thank you Mark My colleagues and I will now answer your questions joining us for the Q&A session are doctors, Mark Newman, Kelly Mckee and John Sharkey, Our Chief Scientific Officer, Chief Medical Officer, and Vice President of business development, respectively.
David Dodd: I'll now turn the call over to the operator for instructions on the question and answer period.
David Dodd: Thank you we will now begin the question and answer session to ask a question you May Press Star then one one on your telephone keypad.
Speaker Change: Youre using a speakerphone please pick up your handset before pressing the keys.
David Dodd: Withdraw your question. Please press star one again.
Speaker Change: At this time, we will pause momentarily to assemble our roster.
Speaker Change: And our first question comes from Jonathan Aschoff with Roth Capital Partners. Your line is open.
Thank you good afternoon, guys I got a few questions I was wondering.
Speaker Change: The urgency of the M Hawks threat could you, possibly be part of sort of relatively near term response.
Speaker Change: Selling product without clinical testing.
Speaker Change: That testing that you said now supposed to start around year end 'twenty five.
Jonathan Aschoff: Thank you Jonathan first of all Im I jumped on the phone a little bit early there a minute ago, so I apologize to everyone.
Speaker Change: Yes.
Speaker Change: The answer is we don't know usually you cannot but there is opportunity.
Speaker Change: With the latitude of working with WH show through emergency use licensing and depending on on the recognized need currently there is a major need worldwide. In fact Africa alone as stated repeatedly that they need 20% to 25 million doses right now and it.
Here's the most they will be able to receive from the current supplier.
Speaker Change: As no more than $5 million by year end of this year. So that just underscores the critical importance of additional supply options, but keep in mind. What we have done is we've produced more than enough product to support what we believe will be necessary for a clinical need.
Speaker Change: And then we have additional to use for additional clinical valuation, perhaps that that could end up being to where we are.
Speaker Change: Actually we're able to deliver some and be able to book revenues, but time will tell on that and we'll know more as we proceed through this year.
Speaker Change: Okay.
Speaker Change: Along that same line how are you working with international partners done the EU regulatory agencies in low income countries in Africa, maybe insure in the not too distant future.
Speaker Change: Manufacturing there.
Speaker Change: There's a whole issue of.
Speaker Change: I would say equitable.
Speaker Change: <unk> access on a global basis, and especially in low income countries.
Speaker Change: As a major.
Speaker Change: A major factor on our focus and our discussions we have been in discussions with Representatives of Africa, CDC and health Ministries in Africa with European colleagues agents regulatory agencies et cetera for over a year now or a year and a half plus and we continue to.
Speaker Change: Keep them updated they are aware of where we are with our status. What we believe we may have we haven't been specific with at this point in time, but we are keeping them.
Speaker Change: Much update of this includes the Africa vaccine manufacturing initiative also so just to know UNICEF UNICEF has that RF and active RFP.
Speaker Change: Funding and support.
Speaker Change: In close contact with that organization. So we've been spending quite a bit of time over the last two years building. These relationships getting past the point of just getting to know one another and then becoming much more substantive.
Speaker Change: Our discussions with them.
Speaker Change: Okay, and then lastly, David.
Speaker Change: What's actually needed to start the next good depth in trial on is that still second quarter 'twenty five to start enrollment or really no guidance right. Now like are you trying to maybe see if somebody else will funded before starting it with your own funding.
Speaker Change: You bet.
Speaker Change: Basically what we're looking at is we want to we're continuing to manufacture the product.
Speaker Change: We've had some issues with the with the cell line. We had started with so we've been working on that we have everything pretty much outlined not fully outline flipped from the clinical trial operations I believe we have selected our <unk> at this stage, but it really is about advancing that have sufficient.
Speaker Change: Our product supply investigators are identified so we've got that but were looking now at probably a more into.
Speaker Change: I would say in the in the mid to latter part of next year that we would be initiating the clinical trial.
Speaker Change: Okay Alright.
So that's a substantial pushback alright.
Speaker Change: Thank you very much Dan Youre welcome. Thank you.
Speaker Change: Thank you. Our next question comes from Robert Leboyer with Noble capital markets. Your line is open.
Speaker Change: Okay.
Speaker Change: Well firstly congratulate.
Speaker Change: While the progress you've made and Dave also congratulations on leading the company through what must have felt like the value that these past two or three years.
Speaker Change: Mike.
Speaker Change: My question has to do with the clinical trials and testing for MDA.
Speaker Change: <unk>.
Speaker Change: The product is going to be tested in humans, but since this is a preventive.
Speaker Change: Vaccine.
Speaker Change: You can't test the protection by giving them the actual buyer see if it works. So could you just elaborate a little bit on how.
Speaker Change: Or are you going to test efficacy and safety.
Speaker Change: Yes, I'm going to call on a doctor John Sharkey because he is also our executive lead for Geo MVA, which is the <unk> smallpox vaccine candidate John.
Speaker Change: So the standard the typical role.
Speaker Change: Previously that one does nonhuman primates.
Speaker Change: So.
Speaker Change: Nonhuman primates.
Speaker Change: With animal testing Theres always a move to move to lower animals.
Speaker Change: But not as much.
Speaker Change: Z.
Speaker Change: Rabbits.
Speaker Change: Ferrets for other things for different disease States.
Speaker Change: We are having those discussions with the regulator.
Speaker Change: And again.
Speaker Change: Confirm that we will need.
Speaker Change: B trial in an animal, but if we weren't.
Speaker Change: Animal when we use the important thing here is.
Speaker Change: These are relatively short term studies, so any animal studies, we have to do we could probably run in parallel with our clinical trial, but it is not it.
Speaker Change: Yes.
Speaker Change: So they would run apparel.
Speaker Change: Even if they're required to have no significant impact on the course.
Speaker Change: Medical trial.
Okay, and when do you run the clinical trial any estimates at this point as to numbers of patients or endpoints.
Speaker Change: Well the endpoint is going to be any logical one.
Speaker Change: As far as numbers we.
Speaker Change: We are in.
Speaker Change: Additional round of clarification with the regulators specifically on the question of what the numbers, we think were going.
Speaker Change: Going to need.
And we're granting the protocol.
Speaker Change: Pete.
Speaker Change: We're going to probably be in the range of 400 basin, but.
Speaker Change: Subjects, but it has to be we have to reach agreement with the regulators on that but based on our typical.
Speaker Change: We're estimating in the range of 100 or so subjects.
Speaker Change: Subjects will be required.
Speaker Change: Okay. That's helpful. Thank you very much.
Speaker Change: Sure.
Speaker Change: Let me ask also Robert as a follow up to ask Dr. Kelly My key just to comment all the regions in which we will plan to conduct a clinical program in support of G. O N V. A.
Speaker Change: Kevin.
Speaker Change: Sorry, sorry, alright, thanks, a lot Sharon mute myself.
Robert Leboyer: Thanks Robert.
Speaker Change: So the.
Speaker Change: Our current thinking is we will do this steady probably primarily in Europe.
Speaker Change: Central Eastern Europe.
Speaker Change: Just because it's a low cost area.
Speaker Change: But we're also going to have at least one trial site in sub Saharan Africa.
Speaker Change: Sure.
Speaker Change: To address the sum of it some of the potential questions that might arise.
<unk>.
Speaker Change: Sure.
Speaker Change: It's immune and immune response in the African populations.
Speaker Change: As you know there is.
Speaker Change: There is an approved NDA vaccine already.
Speaker Change: And Nordics.
Speaker Change: <unk>.
Speaker Change: And our trial will be a non inferiority study.
Speaker Change: Mean response of our vaccine to to that <unk>, which we.
Speaker Change: We anticipate should be.
Speaker Change: No.
Speaker Change: Jim you're basically.
Speaker Change: Okay.
Yes.
Speaker Change: Okay. Thank you very much.
Speaker Change: Thank you.
Speaker Change: Thank you.
Speaker Change: Again, if you'd like to ask a question. Please press star one one.
Speaker Change: Our next question comes from James Molloy with Alliance Global Partners. Your line is open.
Speaker Change: Hello, This is laura or outline for Jim Malloy. Thank you for taking the questions.
Speaker Change: So as mentioned data Readouts expected later this year for the phase III COVID-19 booster vaccine trial of CMO fourth one.
Speaker Change: So when should we anticipate data readouts spread the remaining two phase III trials and immuno compromised patients as well as any other timelines for these trials here.
Speaker Change: Sure I'll ask Kelly to provide the update on the plans in that area. Okay.
Speaker Change: Sure. So the study that we have ongoing in the.
Speaker Change: And our blood cancer patients that have received.
Speaker Change: Cell transplant therapies.
Speaker Change: We expect some some readouts for that.
Speaker Change: To be to be disclosing some readouts from that I should say.
Speaker Change: Sometime during the early part early to mid part of 2026.
Speaker Change: We are in discussions.
Speaker Change: About <unk>.
Speaker Change: Modifying the design of our studies in this population.
Speaker Change: And so that would sort of influence the.
Speaker Change: The timing of.
Speaker Change: No.
Speaker Change: Readouts on the current currently enrolling trial.
Speaker Change: As for the <unk> study.
Speaker Change: As you May recall Thats, an investigator initiated trial being conducted at the Citigroup Medical Center in California.
Speaker Change: They have they are in the process of opening up an additional city of hope site beyond the main campus in Duarte.
Speaker Change: And just as soon as that site openings, we expect enrollment to.
Speaker Change: To proceed.
Speaker Change: And we're hopeful to have that study fully enrolled by the end of this year.
Speaker Change: There will be some presentations of the interim data.
Speaker Change: The.
Speaker Change: So it is.
Speaker Change: A Simon two stage design and after the first stage.
Speaker Change: The SMB met in May.
Speaker Change: You may remember from our last call.
The decision was made to proceed with the ruling.
Speaker Change: Enrolling.
Speaker Change: CMO four ish, one arm and not the mrna arm.
Speaker Change: And so there's going to be some presentations that data.
Speaker Change: International conferences.
Speaker Change: And there is a.
Speaker Change: A publication.
Speaker Change: Dean being created.
Speaker Change: For that data as well so.
Speaker Change: There's going to be information coming out about that trial hopefully.
Speaker Change: Before the end of the year.
Speaker Change: Thank you that's very helpful.
Speaker Change: And also with all the uncertainty that's going on in Washington, right now, particularly when it comes to you know pulling back on COVID-19 funding.
Speaker Change: How do you think these changes might affect the company moving forward, especially with the.
Speaker Change: The BARDA project Nextgen sure that's in place.
Speaker Change: So excellent question.
Speaker Change: We've been receiving that question since <unk>.
Speaker Change: Even before the inauguration as you might imagine.
Speaker Change: Pardon me off well.
Speaker Change: What we know is the following week, we routinely are in touch with with BARDA, including scheduled once a week call between our team and their team that continues to be a very positive call supported call. We continue to provide what were requested to provide in terms of our.
Speaker Change: Our development side of <unk> for.
Speaker Change: For the program at all.
Speaker Change: And so far every every every indication we've had as business as usual, we're continuing to perform theres been no no direction.
Speaker Change: Directionally to slow up Theres been no direction to change anything other than to move forward with the with a repeatedly underscored statement that were to be able to start the clinical trial before year end. So basically in Q4. So we're working at this time because were working off that assumption.
Speaker Change: And it would be our certainly desire to continue working on that assumption and Meanwhile, our CRO has confirmed all 80 sites that we need so that part is we'll be ready to go and what we.
Speaker Change: Our charged with doing as all the regulatory filings, which we're doing on time and file some even I think it was yet this week if not the end of last week to be prepared to be able to initiate the trial in schedule, where we're working also with the manufacturer of the product. So I can't be any more specific that but that literally is where we are the discussions continue.
Speaker Change: We are aware that there have been a couple of pauses.
Speaker Change: That have been incurred or have been directed to occur but so far.
Again as recently as I guess today and the discussions are to continue with everything we're doing.
Speaker Change: Got it. Thank you well, let me let me let me just add just one thing I have no idea no one knows because theres been no disclosure of y.
Speaker Change: We're asked to Pauls so.
Speaker Change: And so we're focused on what we're doing what we do know is that our vaccine was selected to be in this program specifically and this was I mentioned this in my previous comments, but it was underscored by HHS, our Aspira <unk>.
Speaker Change: Press release that they issued at the time of the announcement is is the specific reasons, we were selected as because thus far our clinical data has demonstrated.
Speaker Change: Protective immunity and a much broader across a much broader array of the emerging variance than what we've seen with the first generation vaccine, meaning we don't have to continuously reconfiguring. We showed with the with our original construct from the Wuhan strain through the Omicron SPV one five.
Speaker Change: Without any revisions versus area, which was true for mrna and then secondly, our durability or how long does it last our data is has been indicating eight to 12 months, which is about twice what we're seeing.
Speaker Change: With the first generation and the desire stated for a for a next generation COVID-19 vaccine was to identify vaccine candidates that have the potential to give more robust response against variance. So we feel at least so far we've checked that all and then secondly to improve upon.
Speaker Change: <unk>.
Speaker Change: The disappointing durability of three to six months, that's been observed in the real world for the mrna and I guess also the Novavax vaccine and so we continue to stay focused because of that and continue to have our discussions and continue to share information with BARDA. So let's.
Speaker Change: Our working model.
Speaker Change: Thank you. This concludes our question and answer session I would like to turn the conference back over to David Dodd for any closing remarks.
David Dodd: Thank you and thank you everyone for participating in today's update reviewing our 2024 achievements our progress.
David Dodd: And our outlook for 2025 as well as beyond.
David Dodd: Your interest is greatly appreciated and we look forward to our continued ongoing interactions.
Speaker Change: I always feel that we want to acknowledge and thank the <unk> board of directors and advisers as well as our staff and the many other parties.
David Dodd: Who continue to support us towards achieving success.
David Dodd: We remain committed to providing meaningful career development opportunities for highly competitive quality oriented individuals seeking to disrupt the current paradigm of cancer therapies infectious disease vaccines, where most proud and appreciative of our team, including those external partners, who contribute and continue to contribute to.
David Dodd: The progress success underway at <unk> for all of US It is a great pleasure, serving our shareholders and being part of this team. We appreciate their ongoing words of encouragement and support our overriding goal is to improve lives worldwide by our development and commercialization of novel critically needed cancer therapies and infects.
David Dodd: This disease vaccine and with that I want to wish everyone to have a safe and enjoyable day and evening. Thank you.
Speaker Change: The conference has now concluded. Thank you for attending today's presentation you may now disconnect.
David Dodd: Okay.
David Dodd: Yes.
David Dodd: Yeah.
David Dodd: [music].
Okay.
David Dodd: Yes.
David Dodd: Okay.
David Dodd: [music].
David Dodd: Okay.